A Phase 1 Study of LY2875358 in Patients With Advanced Cancer

Trial Profile

A Phase 1 Study of LY2875358 in Patients With Advanced Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Emibetuzumab (Primary) ; Erlotinib; Trametinib
  • Indications Bone metastases; Cancer; Colon cancer; Gastrointestinal cancer; Liver cancer; Liver metastases; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 14 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 31 Mar 2017.
    • 10 Oct 2016 Results (n=37) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top